Tubulis generates uniquely matched antibody-drug conjugates with superior biophysical properties that have demonstrated durable on-tumor delivery and long-lasting anti-tumor activity in preclinical models. The two lead programs from their growing pipeline, TUB-040, targeting NaPi2b, and TUB-030, directed against 5T4, are being evaluated in the clinic in high-need solid tumor indications. Tubulis will solidify our leadership position by continuing to innovate on all aspects of ADC design leveraging our proprietary platform technologies. The company goal is to expand the therapeutic potential of this drug class for our pipeline, our partners and for patients.
Tubulis
Lysine Building
Route de la Corniche 4
1066 Epalinges
Keywords
